103 related articles for article (PubMed ID: 2788499)
1. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
Gill I; Agah R; Hu E; Mazumder A
Cancer Res; 1989 Oct; 49(19):5377-9. PubMed ID: 2788499
[TBL] [Abstract][Full Text] [Related]
2. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
[TBL] [Abstract][Full Text] [Related]
4. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
Berinstein N; Levy R
J Immunol; 1987 Aug; 139(3):971-6. PubMed ID: 3496394
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
6. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
7. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
[TBL] [Abstract][Full Text] [Related]
9. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
10. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate.
LeBerthon B; Khawli LA; Alauddin M; Miller GK; Charak BS; Mazumder A; Epstein AL
Cancer Res; 1991 May; 51(10):2694-8. PubMed ID: 2021947
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
Munn DH; Cheung NK
Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
[TBL] [Abstract][Full Text] [Related]
13. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
[TBL] [Abstract][Full Text] [Related]
15. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.
Epstein AL; Khawli LA; Hornick JL; Taylor CR
Cancer Res; 1995 Jun; 55(12):2673-80. PubMed ID: 7780984
[TBL] [Abstract][Full Text] [Related]
16. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
17. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake.
Hu P; Hornick JL; Glasky MS; Yun A; Milkie MN; Khawli LA; Anderson PM; Epstein AL
Cancer Res; 1996 Nov; 56(21):4998-5004. PubMed ID: 8895756
[TBL] [Abstract][Full Text] [Related]
18. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
20. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
Zhang WX; Guo J; Lin BH; Meng SN; Wang XP; Xie Y; Zheng W; Zhang YT; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):41-4. PubMed ID: 17649726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
